Processa Pharmaceuticals, Inc. - Kapitalisasi Buku PCSA

Processa Pharmaceuticals (PCSA) relies on long-term patent protection for modified chemotherapy, ensuring stable revenue driven by the inertia of medical protocols. This chart illustrates that the share price is currently at -0.00. Business growth is being fueled by trials of the PCS6422 drug, which reduces treatment toxicity. The current strategy is based on refining existing agents to mitigate side effects, with developments currently in the mid-stages of testing.

Processa Pharmaceuticals, Inc. (PCSA) - Nilai Buku Perusahaan saka 04.07.2022 nganti 26.10.2026

Processa Pharma - rincian analitis lan metrik utama (PCSA)

- rega lan prakiraan konsensus rega:

Bagan bursa Processa Pharmaceuticals|PCSA - Prakiraan konsensus analis

- data kapitalisasi pasar:

Kapitalisasi pasar Processa Pharmaceuticals Inc.|PCSA - Nilai Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Processa Pharmaceuticals|PCSA - Nilai Buku Perusahaan|Nilai Pasar marang Nilai Buku processapharmaceuticals.com|PCSA - Total Aset Perusahaan

- data utang lan likuiditas:

Utang marang Modal Processa Pharmaceuticals|PCSA - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Processa Pharmaceuticals|PCSA - Utang perusahaan|Utang-utang marang aset resik Processa Pharmaceuticals Inc.

Ringkesan analitik perusahaan:Processa Pharmaceuticals

Financial stability is critical for Processa Pharmaceuticals (PCSA) investors, as equity capitalization confirms the company's ability to develop its innovative oncology hub. By analyzing the book value of the enterprise, you can see the net asset value minus liabilities, which allows you to filter out market noise and determine the real fundamental value of the biotech platform for long-term holding.

Pesaing Processa Pharmaceuticals (PCSA)